Unique Phenotypic Characteristics and Clinical Course in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis: A Multicenter US Experience
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Introduction: Ulcerative colitis (UC) associated with primary sclerosing cholangitis (PSC) is a rare phenotype. We aimed to assess patients with UC-PSC or UC alone and describe differences in clinical and phenotypic characteristics, antitumor necrosis factor (TNF) therapy, and long-term clinical outcomes. Methods: This retrospective multicenter cohort study included patients who received a diagnosis of UC from 1962 through 2015. We evaluated clinical factors associated with UC-PSC vs UC alone and assessed associations by using multivariable logistic regression models. Results: Among 522 patients with UC, 56 (10.7%) had PSC. Compared with UC alone, patients with UC-PSC were younger (younger than 20 years) at diagnosis (odds ratios [OR], 2.35; adjusted P = 0.02) and had milder UC severity (adjusted P = 0.05), despite having pancolonic involvement (OR, 7.01; adjusted P < 0.001). In the biologics era (calendar year 2005 to 2015), patients with UC-PSC less commonly received anti-TNF therapy compared with patients with UC (OR, 0.38; adjusted P = 0.009), but their response rates were similar. Fewer patients with UC-PSC received corticosteroids (OR, 0.24; adjusted P = 0.005) or rectal 5-aminosalicyte acid (OR, 0.26; adjusted P < 0.001). Other differences were identified that were not statistically significant in a multivariable model: patients with UC-PSC more commonly were male, had lower rates of smoking, and had higher rates of colorectal cancer and colectomy. Discussion: This study identified a unique phenotype of UC with concurrent PSC, which had different clinical behavior compared with UC only. These phenotypic characteristics can help identify high-risk patients with UC before PSC is diagnosed and guide different management and monitoring strategies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PSC-IBD generally runs a mild disease course.351,352,357”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [357]
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.008 · Cited by 17,893
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Loftus, E. V. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.063 · Cited by 3,117
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R., Fevery, J., Kalloo, A., Nagorney, D. M., Boberg, K. M., Shneider, B., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,224
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
Loftus, E. V., Harewood, G. C., Loftus, C. G., Tremaine, W. J., Harmsen, W. S., Zinsmeister, A. R., Jewell, D. A., & Sandborn, W. J. (2005) · Gut · doi:10.1136/gut.2004.046615 · Cited by 777
The International IBD Genetics Consortium (IIBDGC), Ellinghaus, D., International Genetics of Ankylosing Spondylitis Consortium (IGAS), International PSC Study Group (IPSCSG), Genetic Analysis of Psoriasis Consortium (GAPC), Psoriasis Association Genetics Extension (PAGE), Jostins, L., Spain, S. L., Cortes, A., Bethune, J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3528 · Cited by 751
Boonstra, K., Weersma, R. K., van Erpecum, K. J., Rauws, E. A., Spanier, B. W. M., Poen, A. C., van Nieuwkerk, K. M., Drenth, J. P., Witteman, B. J., Tuynman, H. A., et al. (2013) · Hepatology · doi:10.1002/hep.26565 · Cited by 725
Research works printed but not linked: 1
- Dignass, 2015, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management (Spanish version), Rev Gastroenterol Mex., 80, 32
Cited by
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
The microbiota and the gut–liver axis in primary sclerosing cholangitis
Hov, J. R., & Karlsen, T. H. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00690-y · Cited by 139
Inflammatory bowel disease and primary sclerosing cholangitis: One disease or two?
van Munster, K. N., Bergquist, A. M., & Ponsioen, C. Y. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.09.031 · Cited by 139
Primary sclerosing cholangitis
Manns, M. P., Bergquist, A. M., Karlsen, T. H., Levy, C., Muir, A. J., Ponsioen, C. Y., Trauner, M., Wong, G. L., & Younossi, Z. M. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00600-x · Cited by 80
Zhang, R., Lauwers, G. Y., & Choi, W. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac090 · Cited by 53
Barnes, E. L., Holubar, S. D., & Herfarth, H. H. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab025 · Cited by 42
Attauabi, M., Zhao, M., Bendtsen, F., & Burisch, J. M. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa167 · Cited by 32
Maal, A. B., Shahrbaf, M. A., Sadri, B., Hossein‐Khannazer, N., Mansournia, M. A., & Vosough, M. (2023) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjad157 · Cited by 23
Primary sclerosing cholangitis
von Seth, E., Karlsen, T. H., Tanaka, A., Ponsioen, C. Y., & Bergquist, A. M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02582-6 · Cited by 17
Fauze, F. (2022) · Iraqi National Journal of Nursing Specialties · doi:10.58897/injns.v35i1.505 · Cited by 14
Yano, K., Moroi, R., Shiga, H., Tarasawa, K., Shimoyama, Y., Kuroha, M., Hamada, S., Kakuta, Y., Fushimi, K., Fujimori, K., et al. (2021) · JGH Open · doi:10.1002/jgh3.12693 · Cited by 11
Autorinnen/Autoren, & Collaborators (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2558-5204 · Cited by 10
Zhang, R., Wang, D., Lauwers, G. Y., & Choi, W. (2024) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002255 · Cited by 10
Hong, R., Li, Z., Li, M., & Dai, Y. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241311165 · Cited by 10
Sleiman, J., Francis, F. F., Coelho–Prabhu, N., & Hashash, J. G. (2025) · Annals of Gastroenterology · doi:10.20524/aog.2025.0945 · Cited by 9
Sayed, A., Assis, D. N., Silveira, M. G., Deng, Y., Ciarleglio, M. M., Gaidos, J. K. J., Proctor, D. D., & Al‐Bawardy, B. (2023) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002510 · Cited by 7
Moroi, R., Yano, K., Tarasawa, K., Shimoyama, Y., Naito, T., Shiga, H., Hamada, S., Kakuta, Y., Fushimi, K., Fujimori, K., et al. (2022) · Inflammatory Intestinal Diseases · doi:10.1159/000529338 · Cited by 7
Wang, S., Farokhian, A., & Shen, B. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100199 · Cited by 6
Polygenic risk score predicts risk of primary sclerosing cholangitis in inflammatory bowel disease
Wang, M., Friton, J. J., Raffals, L. E., Leighton, J. A., Pasha, S. F., Picco, M. F., Monroe, K. M., Nix, B. D., Newberry, R. D., & Faubion, W. A. (2023) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2023-001141 · Cited by 6
Self-citationIs Ulcerative Colitis Associated With Primary Sclerosing Cholangitis an Undertreated Condition?
van der Have, M., & Oldenburg, B. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz211 · Cited by 5
Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease
Okada, H., Sugimoto, S., Kayashima, A., Mikami, Y., Kanai∥, T., Nakamoto, N., Collaborators, K. P., Yoshimatsu, Y., Kiyohara, H., Nakadai, Y., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02388-3 · Cited by 4
Zhang, M. Y., Xu, T. M., Sun, Y. H., Chu, X. T., Ruan, G., Bai, X., Lv, H., Yang, H. B., Shu, H. J., & Qian, J. (2024) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13321 · Cited by 4
Voulgaris, T. A., Fotios, F., Mousourakis, K., Euaggelos, C., Konstantinos, A., George, M., Konsantinos, T., Fytili, P., Michopoulos, S., Nikoletta, M., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.01.009 · Cited by 3
Niu, C., Zhang, J., Bhatta, P. D., Zhu, K., Jadhav, N., Okolo, P. I., III, Mushtaq, A., & Daglilar, E. S. (2025) · Journal of Internal Medicine · doi:10.1111/joim.70026 · Cited by 2
Sebode, M., Bantel, H., Baumann, U., Bufler, P., Demir, M., Dold, L., Keitel, V., Klein, R., Kremer, A. E., Jansen, P. L., et al. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2769-2475 · Cited by 2
Primary Sclerosing Cholangitis
Bowlus, C. L. (2020) · Springer eBooks · doi:10.1007/978-3-030-51709-0_25 · Cited by 1
It’s Not Always Infections When It Comes to Resource-Poor Countries: A Fascinating Case Report
Swaminathan, G., Sethi, A. K., PATRIZI, S., Elhawary, A., Al-Howthi, N., Saha, U., & Defillo-Lopez, C. (2024) · Cureus · doi:10.7759/cureus.66469
Malignancy Screening in Primary Sclerosing Cholangitis
Saeedi, B. J., & Forman, L. (2026) · Current Hepatology Reports · doi:10.1007/s11901-025-00717-3
Metadata
- Authors
- Wang, M.-H., Mousa, O. Y., Friton, J. J., Raffals, L. E., Leighton, J. A., Pasha, S. F., Picco, M. F., Cushing, K. C., Monroe, K., Nix, B. D., Newberry, R. D., & Faubion, W. A.
- Affiliations
- Mayo Clinic (US)
- Washington University in St. Louis (US)
- Corresponding author
- Wang, Ming-Hsi
- ORCID
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-10-18
- Volume
- 26
- Issue
- 5
- Pages
- 774-779
- ISSN
- 1078-0998 (ISSN-L)
- 1536-4844
- PMC
- PMC7534392
- OpenAlex
- W2980461461
- Cited by
- 27
- References
- 38
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 5 · 2021: 2 · 2020: 2 · 2019: 1
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Inflammatory Bowel Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Helmsley Charitable Trust
- National Institutes of Health (T32DK007130)
- Washington University Institute of Clinical and Translational Sciences (UL1TR000448)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ulcerative colitis, primary sclerosing cholangitis
- MeSH terms
- Tumor Necrosis Factor Inhibitors, Adolescent, Adult, Colitis, Ulcerative, Female, Humans, Male, Middle Aged, Phenotype, Retrospective Studies, Severity of Illness Index, Sex Factors, United States, Cholangitis, Sclerosing, Logistic Models, Odds Ratio, Treatment Outcome, Disease Management, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.